0001628280-26-035533
SEC filingQ3 revenue declined 24.9% to $2.6M from supply chain disruptions, driving operating loss of $419K, but net income surged 774% to $2.4M due to AXIS software sale proceeds.
Escalon's Q3 FY2026 revenue of $2.6 million declined 24.9% from $3.5 million in the prior year, primarily because Sonomed sales decreased due to backorders from a significant vendor's fulfillment constraints related to shifting demand. Trek product sales also declined compared to the prior year, which benefited from higher-than-average order volume and fulfillment. These supply chain issues highlight the company's vulnerability to external vendor dependencies in the ophthalmology device market, potentially pressuring near-term revenue recovery as diversification efforts remain critical for investors to watch.
Gross profit fell 40.8% to $946.7 thousand, with gross margin at 36.3%, reflecting the revenue contraction and challenges from increased costs of imported raw materials, components, and finished goods as noted in management commentary. This margin dynamic underscores ongoing profitability risks tied to global sourcing, where cost inflation could further erode margins if not offset by pricing power or supply efficiencies.
Operating income deteriorated to a $419.3 thousand loss from prior-year profit of $276 thousand (-251.9% change), driven by the topline decline and an increase in selling, general, and administrative expenses. The SG&A rise stemmed mainly from higher bonus, payroll and fringe benefits, consulting, and exhibits expenses during the three months ended March 31, 2026, despite some offset from lower commissions. Management's focus on cost monitoring is essential given the company's history of operations not generating sufficient revenues for profitability.